

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A multifunctional compound, expressed in and secreted by a mammalian host cell as a fully functional heterodimer of two polypeptide chains, wherein one of said polypeptide chains comprises the constant CH1-domain of an immunoglobulin heavy chain and the other polypeptide chain comprises the constant CL-domain of an immunoglobulin light chain, wherein said polypeptide chains of said multifunctional compound further comprise, fused to said constant domains at least ~~three~~ two polypeptide functional domains having different receptor or ligand functions, wherein at least one of said functional domains comprises a non-immunoglobulin portion having receptor or ligand function, wherein further at least two of said different functional domains lack an intrinsic affinity for one another and wherein said polypeptide chains are linked via said immunoglobulin constant domains.

2. (Previously presented) The multifunctional compound of claim 1, wherein the functional domains having receptor or ligand function, are C-and/or N-terminally linked to one or both of said constant immunoglobulin domains.

3. (Cancelled)

4. (Previously presented) The multifunctional compound of claim 1, comprising four functional domains having receptor or ligand function.

5. (Cancelled)

6. (Previously presented) The multifunctional compound of claim 1, wherein at least one of said functional domains having receptor or ligand function, comprises a scFv-fragment or a functional part thereof.

7. (Currently amended) The multifunctional compound of claim ~~6~~4, wherein at least one of said functional domains having receptor- or ligand function, is a T-cell costimulatory ligand, an antigen binding region specific for a tumor associated antigen, or a proteinaceous compound providing the primary activation signal for T-cells.

8-18. (Cancelled)

19. (Previously presented) The multifunctional compound of claim 1, wherein said constant domain of an immunoglobulin light chain is of the  $\kappa$  type.

20. (Previously presented) The multifunctional compound of claim 1, wherein said immunoglobulin constant domains and said functional domains having receptor or ligand function are connected by a polypeptide linker.

21. (Previously presented) The multifunctional compound of claim 20, wherein said polypeptide linker comprises an Ig-hinge region or a plurality of glycine, alanine and/or serine.

22. (Previously presented) The multifunctional compound of claim 21, wherein said Ig-hinge region is an IgG hinge region.

23. (Previously presented) The multifunctional compound of claim 22, wherein the IgG hinge region is the upper hinge region of human IgG.

24. (Cancelled)

25. (Cancelled)

26. (Previously presented) The multifunctional compound of claim 1, wherein said CH1 domain is linked to a histidine tag, GST, Staphylococcus protein A, Lex A, a FLAG-tag or a MYC-tag.

27-41. (Cancelled)

42. (New) The multifunctional compound of claim 6, wherein said scFv fragment or said functional part thereof comprises the VH and the VL regions of the human anti-human EpCAM antibody.

43. (New) The multifunctional compound of claim 42, wherein said VH and VL regions of the human anti-human EpCAM antibody comprise the amino acid sequence disclosed in Figure 55.

44. (New) The multifunctional compound of claim 6, wherein at least one of said functional domains comprising a non-immunoglobulin portion having receptor or ligand function, is an immunomodulating effector molecule or fragment thereof.

45. (New) The multifunctional compound of claim 44, wherein said immunomodulating effector molecule or said fragment thereof is selected from the group consisting

of cytokines, chemokines, macrophage migration factor (MIF), T-cell receptors and soluble MHC molecules.

46. (New) The multifunctional compound of claim 45, wherein said cytokines are selected from the group consisting of interleukins, interferons, GM-CSF, G-CSF, MCSF, TNFs and VEGF.

47. (New) The multifunctional compound of claim 46, wherein said at least three functional domains having different receptor or ligand function, comprise GM-CSF, IL2 and an scFv fragment comprising the VH and the VL regions of the human-anti-human EpCAM antibody.

48. (New) The multifunctional compound of claim 47, wherein said GM-CSF and said IL-2 are C-terminally linked to said constant CH1 or CL domains and wherein said scFv fragment comprising the VH and the VL regions of the human anti-human EpCAM antibody is N-terminally linked to said constant CH' or CL domains.